Published in Pflugers Arch on January 01, 1971
Methods of the assessment of the effect of drugs on liver blood flow in man. Br J Clin Pharmacol (1979) 0.95
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Prognosis of treated hypertension. Changes in life expectancy and causes of death between 1952 and 1967. Q J Med (1970) 3.71
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol (1979) 3.32
Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain (1975) 2.80
Incidence of a positive direct coombs test in patients on alpha-methyldopa. Lancet (1966) 2.44
Drugs and the liver. Clin Pharmacol Ther (1998) 2.23
Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet (1967) 2.22
Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin Sci (1971) 2.11
Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology (1989) 2.07
Hypertension and hyperuricaemia. Lancet (1966) 1.86
The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos (1996) 1.86
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest (1974) 1.85
Dose-dependent enzyme induction. Clin Pharmacol Ther (1973) 1.84
Clinical implications of enzyme induction. Ann N Y Acad Sci (1971) 1.76
Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J (1973) 1.76
Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet (1987) 1.70
Changes in liver blood flow during enzyme induction. Biochem Pharmacol (1971) 1.65
Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos (1974) 1.63
Kinetics of warfarin absorption in man. Clin Pharmacol Ther (1974) 1.63
Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet (1966) 1.61
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther (1974) 1.61
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: current status. Br J Clin Pharmacol (1994) 1.53
Treating mild hypertension. Br Med J (Clin Res Ed) (1985) 1.49
The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol (1987) 1.49
The effect of phenobarbitone-induction on vitamin D metabolism. Clin Sci (1972) 1.46
Postgraduate education in therapeutics: experience in Merseyside. Br Med J (1978) 1.44
Hypertension in the young. Q J Med (1967) 1.42
Digital heart rate meter. Cardiovasc Res (1971) 1.33
Regulatory challenges, reimbursement, and risk-benefit assessment. Clin Pharmacol Ther (2010) 1.32
Immediate decrease by hydrocortisone of the plasma half-life of antipyrine. Br J Pharmacol (1973) 1.28
The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol (1986) 1.26
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS (1994) 1.25
Methyldopa and haemolytic anaemia. Lancet (1966) 1.21
Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension (1988) 1.17
The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sci II (1972) 1.16
Urinary excretion of chlorothiazide in rats before and after phenobarbitone administration. Experientia (1972) 1.12
Combined action of methyldopa and bethanidine. Evidence for a synergistic effect. Lancet (1966) 1.11
Effects of methyldopa on prolactin and growth hormone. Br Med J (1976) 1.11
Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin Pharmacol Ther (1974) 1.09
Glucose tolerance in hypertensive patients on long-term diuretic therapy. Lancet (1967) 1.09
Jogger's blockade. Br Med J (Clin Res Ed) (1982) 1.08
Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol (1988) 1.07
Propranolol in the control of blood pressure: a dose-response study. Clin Pharmacol Ther (1980) 1.05
The effect of enzyme induction on diazepam metabolism in man. Br J Clin Pharmacol (1979) 1.05
Interactions of benzodiazepines with warfarin. Br Med J (1972) 1.05
Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr (1987) 1.00
Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. Eur J Clin Pharmacol (1988) 1.00
Which beta blocker? Br Med J (Clin Res Ed) (1983) 1.00
Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man. Eur J Clin Pharmacol (1983) 0.99
Clinical implications of enzyme induction. Basic Life Sci (1975) 0.99
Increased glucuronidation of bilirubin in man and rat by administration of antipyrine (phenazone). Clin Sci Mol Med (1974) 0.98
[Clinical pharmacokinetics of Articain after intraoral and intramuscular applications]. SSO Schweiz Monatsschr Zahnheilkd (1983) 0.96
Concern about records of fibrosing colonopathy study. Lancet (2001) 0.96
Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol (1985) 0.96
The effects of long term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol (1973) 0.95
Methods of the assessment of the effect of drugs on liver blood flow in man. Br J Clin Pharmacol (1979) 0.95
Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) (1983) 0.95
[Ranitidine-nifedipine interaction]. Dtsch Med Wochenschr (1984) 0.94
Pharmacokinetics of unlabelled and 14C-labelled pindolol in uraemia. Eur J Clin Pharmacol (1974) 0.94
Advancing the science of medicines regulation: the role of the 21st-century medicines regulator. Clin Pharmacol Ther (2012) 0.94
6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine. Br J Clin Pharmacol (1982) 0.94
Enzyme induction and renal function in man. Br J Clin Pharmacol (1977) 0.94
Should every survivor of a heart attack be given a beta blocker? Part II. Evidence from a clinical pharmacological standpoint. Br Med J (Clin Res Ed) (1982) 0.93
Clinical pharmacology and therapeutics in undergraduate medical education in the UK: the future. Br J Clin Pharmacol (1994) 0.93
Risk sharing and payment by results. Clin Pharmacol Ther (2008) 0.92
Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol (1989) 0.92
Proceedings: Digoxin dosage in patients with impaired kidney function. Br J Pharmacol (1972) 0.92
Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man. Am J Physiol (1979) 0.92
Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet (1987) 0.92
[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine]. Dtsch Med Wochenschr (1983) 0.90
Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin. Clin Pharmacol Ther (1979) 0.89
Effect of cisapride and metoclopramide on digoxin bioavailability. Eur J Drug Metab Pharmacokinet (1987) 0.88
An Indochinese refugee psychiatric clinic: culturally accepted treatment approaches. Am J Psychiatry (1980) 0.88
Large-dose urography. Is there an optimum dose? Lancet (1967) 0.88
Influence of ranitidine on plasma metoprolol concentrations. Br Med J (Clin Res Ed) (1983) 0.87
Vasodilators in heart failure. Br Med J (Clin Res Ed) (1982) 0.87
Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process. Clin Pharmacol Ther (2010) 0.87
Treatment of Weber-Christian panniculitis with cyclosporine A. Rheumatol Int (1987) 0.85
Estimation of the biliary excretion of different cephalosporins utilizing retrograde cholangio-pancreatography (ERCP). Endoscopy (1981) 0.85
The challenges of orphan drugs and orphan diseases: real and imagined. Clin Pharmacol Ther (2012) 0.85
Post-marketing strategies for medicines. Clin Pharmacol Ther (2007) 0.85
The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study. Klin Wochenschr (1983) 0.84
The effect of antipyrine, phenobarbitol and rifampicin on thyroid hormone metabolism in man. Eur J Clin Invest (1981) 0.83
Divergent effects of different enzyme-inducing agents on endogenous and exogenous testosterone. Eur J Clin Pharmacol (1992) 0.83
European perspective on risk management and drug safety. Clin Pharmacol Ther (2011) 0.83
Selective bilateral and simultaneous catheterization of the inferior petrosal sinus: CRF stimulates prolactin secretion from ACTH-producing microadenomas in Cushing's disease. Clin Endocrinol (Oxf) (1988) 0.83
Dose-dependence of the nifedipine-digoxin interaction? Clin Pharmacol Ther (1986) 0.83
Interaction between the beta-adrenoceptor blockers metoprolol and atenolol with amitriptyline and their effects on oxidative liver metabolism. Br J Clin Pharmacol (1984) 0.83
Clinical experience with atenolol in patients with chronic liver disease. J Clin Pharmacol (1983) 0.82
What is the nephrogram? Lancet (1967) 0.82
The effects of indomethacin and naproxen on zidovudine pharmacokinetics. Br J Clin Pharmacol (1993) 0.82
Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine. Eur J Clin Pharmacol (1985) 0.81
[Influence of salmon calcitonin on acute pancreatitis (author's transl)]. Dtsch Med Wochenschr (1979) 0.81
Liver blood flow and blood volume following chronic phenobarbitone administration. Eur J Pharmacol (1975) 0.81
Early access to new medicines. Clin Pharmacol Ther (2008) 0.81
Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res (1984) 0.81
Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. Ther Drug Monit (1989) 0.81
Influence of inflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol. Biopharm Drug Dispos (1983) 0.80